全文获取类型
收费全文 | 8297篇 |
免费 | 94篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 105篇 |
妇产科学 | 180篇 |
基础医学 | 701篇 |
口腔科学 | 81篇 |
临床医学 | 934篇 |
内科学 | 1888篇 |
皮肤病学 | 84篇 |
神经病学 | 877篇 |
特种医学 | 626篇 |
外科学 | 1369篇 |
综合类 | 15篇 |
一般理论 | 2篇 |
预防医学 | 292篇 |
眼科学 | 219篇 |
药学 | 112篇 |
中国医学 | 6篇 |
肿瘤学 | 865篇 |
出版年
2024年 | 3篇 |
2023年 | 825篇 |
2022年 | 1205篇 |
2021年 | 889篇 |
2020年 | 1019篇 |
2019年 | 505篇 |
2018年 | 236篇 |
2017年 | 334篇 |
2016年 | 289篇 |
2015年 | 212篇 |
2014年 | 749篇 |
2013年 | 325篇 |
2012年 | 227篇 |
2011年 | 76篇 |
2010年 | 335篇 |
2009年 | 306篇 |
2008年 | 85篇 |
2007年 | 101篇 |
2006年 | 63篇 |
2005年 | 52篇 |
2004年 | 37篇 |
2003年 | 47篇 |
2002年 | 52篇 |
2001年 | 40篇 |
2000年 | 26篇 |
1999年 | 60篇 |
1998年 | 57篇 |
1997年 | 42篇 |
1996年 | 59篇 |
1995年 | 52篇 |
1994年 | 33篇 |
1993年 | 17篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1990年 | 10篇 |
1989年 | 7篇 |
1986年 | 1篇 |
1984年 | 1篇 |
排序方式: 共有8392条查询结果,搜索用时 234 毫秒
61.
《Journal of cardiac failure》2020,26(3):270-275
BackgroundAlthough left atrial (LA) mechanical dysfunction in heart failure with preserved ejection fraction (HFpEF) is associated with poor clinical outcomes, the influence of LA myopathy on temporal changes in cardiovascular biomarkers is unclear.Methods and ResultsWe evaluated biomarker correlates of LA myopathy, as defined by reduced LA strain, and the associations of LA strain with longitudinal changes in biomarkers among participants in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial. LA speckle-tracking was performed on baseline echocardiograms of RELAX participants to measure LA reservoir and LA contractile strain. Of the 216 RELAX participants, 169 (78%) had measurable LA strain and biomarker data. Participants with LA reservoir strain below median (13.5%, interquartile range: 10%–22.5%) were older, more likely to have atrial fibrillation, and had higher jugular venous pressure (P < .05 for all). At baseline, higher levels of endothelin-1, N-terminal pro–B-type natriuretic peptide (NT-proBNP), and troponin I were independently associated with lower LA reservoir and contractile strain (Padjusted < .05 for all comparisons). Higher LA reservoir strain (β coefficient per 1-unit increase: −21.2, 95% CI: −38.8, −3.7; P = .02) was independently associated with reduction in NT-proBNP at 24 weeks.ConclusionIn HFpEF, LA myopathy is characterized by elevation in biomarkers of neurohormonal activation and myocardial necrosis. Lower LA function is associated with continued elevation in NT-proBNP over time, suggesting that LA myopathy is associated with persistent congestion in HFpEF. 相似文献
62.
63.
64.
65.
66.
67.
Nicole L. Stout DPT Justin C. Brown PhD Anna L. Schwartz PhD FNP Timothy F. Marshall PhD Anna M. Campbell PhD MBE Larissa Nekhlyudov MD MPH David S. Zucker MD PhD Karen M. Basen-Engquist PhD MPH Grace Campbell PhD MSW RN Jeffrey Meyerhardt MD MPH Andrea L. Cheville MD MSSE Kelley R. Covington MS Jennifer A. Ligibel MD Jonas M. Sokolof DO Kathryn H. Schmitz PhD MPH Catherine M. Alfano PhD 《Cancer》2020,126(12):2750-2758
68.
《Surgery for obesity and related diseases》2022,18(6):762-771
BackgroundNew antidiabetic agents (sodium-glucose cotransporter-2 inhibitor [SGLT2i] and glucagon-like peptide-1 receptor agonist [GLP-1RA]) and metabolic surgery have protective effects on metabolic syndromes.ObjectivesTo compare the changes of metabolic parameters and costs among patients with obesity and type 2 diabetes undergoing metabolic surgery and initiating new antidiabetic agents over 12 months.SettingHong Kong Hospital Authority database from 2006–2017.MethodsThis is a population-wide retrospective cohort study consisting of 2616 patients (1810 SGLT2i, 528 GLP-1RA, 278 metabolic surgery). Inverse probability treatment weighting of propensity score was applied to balance baseline covariates of patients with obesity and type 2 diabetes who underwent metabolic surgery, or initiated SGLT2i or GLP-1RA. Metabolic parameters and direct medical costs were measured and compared from baseline to 12 months in metabolic surgery, SGLT2i, and GLP-1RA groups.ResultsPatients in all 3 groups had improved metabolic parameters over a 12-month period. Patients with metabolic surgery achieved significantly better outcomes in BMI (?5.39, ?.56, ?.40 kg/m2, P < .001), % total weight loss (15.16%, 1.34%, 1.63%, P < .001), systolic (?2.21, ?.59, 1.28 mm Hg, P < .001) and diastolic (?1.16, .50, ?.13 mm Hg, P < .001) blood pressure, HbA1c (?1.80%, ?.77%, ?.80%, P < .001), triglycerides (?.64, ?.11, ?.09 mmol/L, P < .001), and estimated glomerular filtration rate (3.08, ?1.37, ?.41 mL/min/1.73m2, P < .001) after 12 months compared with patients with SGLT2i and GLP1-RA. Although the metabolic surgery group incurred the greatest direct medical costs (US$33,551, US$10,945, US$10,627, P < .001), largely due to the surgery itself and related hospitalization, the total monthly direct medical expenditure of metabolic surgery group became lower than that of SGLT2i and GLP-1RA groups at 7 months.ConclusionBeneficial weight loss and metabolic outcomes at 12 months were observed in all 3 groups, among which the metabolic surgery group showed the most remarkable effects but incurred the greatest medical costs. However, studies with a longer follow-up period are warranted to show long-term outcomes. 相似文献
69.
70.